ATE458499T1 - Verbesserte abgabe von diagnostischen und therapeutischen stoffen an einem zielort - Google Patents

Verbesserte abgabe von diagnostischen und therapeutischen stoffen an einem zielort

Info

Publication number
ATE458499T1
ATE458499T1 AT96918023T AT96918023T ATE458499T1 AT E458499 T1 ATE458499 T1 AT E458499T1 AT 96918023 T AT96918023 T AT 96918023T AT 96918023 T AT96918023 T AT 96918023T AT E458499 T1 ATE458499 T1 AT E458499T1
Authority
AT
Austria
Prior art keywords
diagnostic
destination
targeting species
clearing agent
therapeutic substances
Prior art date
Application number
AT96918023T
Other languages
English (en)
Inventor
Gary Griffiths
Hans Hansen
Serengulam V Govindan
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Application granted granted Critical
Publication of ATE458499T1 publication Critical patent/ATE458499T1/de

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6893—Pre-targeting systems involving an antibody for targeting specific cells clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in addition to T-A and D-M
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/009—Neutron capture therapy, e.g. using uranium or non-boron material
    • A61K41/0095—Boron neutron capture therapy, i.e. BNCT, e.g. using boronated porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1078—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an immunoglobulin, i.e. being an (anti)-anti-idiotypic antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/534—Production of labelled immunochemicals with radioactive label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/90—In vivo diagnostic or in vivo test agent which contains an additional ingredient to reduce the toxicity or side effects of the active ingredient

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
AT96918023T 1995-06-07 1996-06-07 Verbesserte abgabe von diagnostischen und therapeutischen stoffen an einem zielort ATE458499T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48616695A 1995-06-07 1995-06-07
PCT/US1996/008696 WO1996040245A1 (en) 1995-06-07 1996-06-07 Improved delivery of diagnostic and therapeutic agents to a target site

Publications (1)

Publication Number Publication Date
ATE458499T1 true ATE458499T1 (de) 2010-03-15

Family

ID=23930870

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96918023T ATE458499T1 (de) 1995-06-07 1996-06-07 Verbesserte abgabe von diagnostischen und therapeutischen stoffen an einem zielort

Country Status (8)

Country Link
US (2) US5965131A (de)
EP (1) EP0837696B1 (de)
JP (1) JPH11507046A (de)
AT (1) ATE458499T1 (de)
AU (1) AU699216B2 (de)
CA (1) CA2223261C (de)
DE (1) DE69638134D1 (de)
WO (1) WO1996040245A1 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068322A1 (en) * 1988-04-18 2003-04-10 Immunomedics, Inc. Methods of antibody-directed enzyme-prodrug therapy
US6228362B1 (en) 1992-08-21 2001-05-08 Immunomedics, Inc. Boron neutron capture therapy using pre-targeting methods
US5846741A (en) * 1992-08-21 1998-12-08 Immunomedics, Inc. Boron neutron capture therapy using pre-targeting methods
US6172045B1 (en) * 1994-12-07 2001-01-09 Neorx Corporation Cluster clearing agents
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
DE69833876T2 (de) * 1997-11-10 2007-05-24 Cytimmune Sciences, Inc. Zusammensetzungen und verfahren für die gezielte abgabe von faktoren
AU755334C (en) 1998-08-25 2004-02-26 University Of Washington Rapid quantitative analysis of proteins or protein function in complex mixtures
US6361774B1 (en) * 1999-09-17 2002-03-26 Immunomedics, Inc. Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
US6629040B1 (en) 1999-03-19 2003-09-30 University Of Washington Isotope distribution encoded tags for protein identification
EP1187637A2 (de) * 1999-06-07 2002-03-20 Center For Molecular Medicine And Immunology Alpha und beta strahlern angekoppelt zu fragmente im radioimmunotherapie
AU6689401A (en) 2000-06-12 2001-12-24 Univ Washington Selective labeling and isolation of phosphopeptides and applications to proteomeanalysis
DE60129741T2 (de) * 2000-06-20 2008-04-30 Immunomedics, Inc. Zielgerichtete kombinationsimmuntherapie für krebs und infektionskrankheiten
KR100377946B1 (ko) * 2000-07-15 2003-03-29 한국과학기술원 덴드리머를 이용한 단분자막의 제조방법
US7445802B2 (en) * 2000-12-26 2008-11-04 Yeda Research And Development Co. Ltd Site-specific in situ generation of allicin using a targeted alliinase delivery system for the treatment of cancers, tumors, infectious diseases and other allicin-sensitive diseases
US6500630B2 (en) * 2001-01-12 2002-12-31 Mayo Foundation For Medical Education And Research Marker for inflammatory conditions
EP1372741B1 (de) * 2001-03-30 2006-08-09 University of Massachusetts Morpholinobildgebung und therapie
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
IL158969A0 (en) 2001-06-01 2004-05-12 Cornell Res Foundation Inc Modified antibodies to prostate-specific membrane antigen and uses thereof
US7192586B2 (en) 2001-09-20 2007-03-20 Cornell Research Foundation, Inc. Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate specific membrane antigen
AU2003219730A1 (en) * 2002-02-07 2003-09-02 Massachusetts Institute Of Technology Anti-pathogen treatements
US20030157091A1 (en) * 2002-02-14 2003-08-21 Dyax Corporation Multi-functional proteins
EP1487879B1 (de) * 2002-03-01 2012-12-26 Immunomedics, Inc. Punktmutationen bei bispezifischen antikörpern zur verbesserung der clearance-rate
US20040141916A1 (en) * 2003-01-08 2004-07-22 George Sgouros Prevention of systemic toxicity during radioimmunotherapy for intravascularly disseminated cancers
US7771953B2 (en) 2003-01-10 2010-08-10 Millenium Pharmaceuticals, Inc. Methods of diagnosing and treating cancer
WO2005026325A2 (en) * 2003-09-10 2005-03-24 Surromed, Inc, Bivalent targeting of cell surfaces
US20050260131A1 (en) * 2004-05-20 2005-11-24 General Electric Company Pharmaceuticals for enhanced delivery to disease targets
US20060057062A1 (en) * 2004-09-10 2006-03-16 Trotter Dinko G Compositions and methods useful in pretargeted imaging
EP1716870A1 (de) * 2005-04-29 2006-11-02 Bracco Imaging S.p.A. Kontrastmittel für Kernspintomographie mit konzentrationsunabhängiger Empfanglichkeit
US20070009435A1 (en) * 2005-07-06 2007-01-11 Syud Faisal A Compositions and methods for enhanced delivery to target sites
US20070009428A1 (en) * 2005-07-06 2007-01-11 Syud Faisal A Compounds and methods for enhanced delivery to disease targets
US20070010014A1 (en) * 2005-07-06 2007-01-11 General Electric Company Compositions and methods for enhanced delivery to target sites
US20070009427A1 (en) * 2005-07-06 2007-01-11 Syud Faisal A Compounds and methods for enhanced delivery to disease targets
WO2007070680A2 (en) * 2005-12-16 2007-06-21 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Optically detectable probes for identification and treatment of tumors
CA2653530A1 (en) * 2006-06-14 2007-12-21 Ciba Holding Inc. Anti-microbial compositions
IL182956A0 (en) * 2007-05-03 2008-01-20 Yeda Res & Dev Glycan modified soluble receptors and binding proteins and their use
EP2191849B1 (de) 2007-09-26 2018-08-01 National Cerebral and Cardiovascular Center Wirkstoff zur suppression von in vivo auftretenden krankheitserregern
GB0916749D0 (en) 2009-09-23 2009-11-04 Mologic Ltd Peptide cleaning agents
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
CN108129554A (zh) 2010-08-10 2018-06-08 洛桑聚合联合学院 红细胞结合性治疗剂
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
EP2654796A1 (de) 2010-12-21 2013-10-30 Koninklijke Philips N.V. Mittel zur entfernung von biomolekülen aus einem kreislauf
US20140256639A1 (en) * 2013-02-14 2014-09-11 The Regents Of The University Of California Peptoid neutralizing agents
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
SG10202010936RA (en) 2014-02-21 2020-12-30 Ecole Polytecnique Fed De Lausanne Epfl Epfl Tto Glycotargeting therapeutics
WO2015189477A1 (en) 2014-06-13 2015-12-17 Tenboron Oy Conjugates comprising an anti-egfr1 antibody
EP3638296A1 (de) 2017-06-16 2020-04-22 The University Of Chicago Zusammensetzungen und verfahren zur herbeiführung einer immuntoleranz
US11767301B2 (en) 2018-04-09 2023-09-26 Yale University Bi-functional molecules to degrade circulating proteins
US12364766B2 (en) 2018-04-09 2025-07-22 Yale University Bifunctional small molecules to target the selective degradation of circulating proteins
US20230097887A1 (en) 2018-04-09 2023-03-30 Yale University Bi-functional Molecules to Degrade Circulating Proteins
US12485178B2 (en) 2018-04-09 2025-12-02 Yale University Bifunctional small molecules to target the selective degradation of circulating proteins
CN112384239A (zh) 2018-05-09 2021-02-19 芝加哥大学 影响免疫耐受的组合物和方法
AU2021213822A1 (en) 2020-01-31 2022-09-22 Avilar Therapeutics, Inc. ASGPR-binding compounds for the degradation of extracellular proteins
KR20230088731A (ko) 2020-10-16 2023-06-20 자이톡스 테라퓨틱스 아베 사전-표적화 이미징 및 치료를 위한 pna 프로브
TW202308703A (zh) 2021-05-03 2023-03-01 美商亞維拉治療公司 用於降解免疫球蛋白及其他蛋白質之有效asgpr結合化合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993025240A2 (en) * 1992-06-09 1993-12-23 Neorx Corporation Pretargeting methods and compounds
US4624846A (en) * 1983-07-29 1986-11-25 Immunomedics, Inc. Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles
US5525338A (en) * 1992-08-21 1996-06-11 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin conjugates
US4863713A (en) * 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
US5733523A (en) * 1990-12-10 1998-03-31 Akzo Nobel N.V. Targeted delivery of a therapeutic entity using complementary oligonucleotides
US5641625A (en) * 1992-05-22 1997-06-24 Isis Pharmaceuticals, Inc. Cleaving double-stranded DNA with peptide nucleic acids
US5482698A (en) * 1993-04-22 1996-01-09 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin polymer conjugates
WO1994027637A1 (en) * 1993-05-27 1994-12-08 Uwe Wagner Monoclonal anti-idiotypic anti-ca125 antibodies and pharmaceutical compositions containing them
US5705333A (en) * 1994-08-05 1998-01-06 The Regents Of The University Of California Peptide-based nucleic acid mimics(PENAMS)
EP0857071A1 (de) * 1995-09-18 1998-08-12 Mallinckrodt Medical, Inc. (radio)markierte biotin-derivate
AU2052497A (en) * 1996-02-08 1997-08-28 Board Of Regents Of The University Of Washington, The Biotin-containing compounds, biotinylation reagents and methods

Also Published As

Publication number Publication date
EP0837696A4 (de) 2005-09-28
WO1996040245A1 (en) 1996-12-19
EP0837696A1 (de) 1998-04-29
US5965131A (en) 1999-10-12
AU699216B2 (en) 1998-11-26
AU6038496A (en) 1996-12-30
CA2223261C (en) 2010-05-11
CA2223261A1 (en) 1996-12-19
JPH11507046A (ja) 1999-06-22
EP0837696B1 (de) 2010-02-24
DE69638134D1 (de) 2010-04-08
US5958408A (en) 1999-09-28

Similar Documents

Publication Publication Date Title
ATE458499T1 (de) Verbesserte abgabe von diagnostischen und therapeutischen stoffen an einem zielort
DE60130538D1 (de) Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
Nagayoshi et al. Effectiveness of anti–folate receptor β antibody conjugated with truncated Pseudomonas exotoxin in the targeting of rheumatoid arthritis synovial macrophages
BR0008161A (pt) Uso de uma composição terapêutica para tratamento de uma célula tumoral, composição terapêutica, e kit para tratamento de uma célula tumoral
BRPI0418695A (pt) uso terapêutico de anticorpos anti-cs1
BRPI0410129A (pt) uso terapêutico de anticorpos anti-cs1
ES2137354T3 (es) Moleculas de anticuerpo anti-vla4 recombinante.
BR9508402A (pt) Ligante de união construção de fator de tecido composição farmacêutica kit e uso de um ligante de união
DE69703121D1 (de) Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit
HUP9901562A2 (hu) Anti-CEA monoklonális antitestek, az ezeket tartalmazó konjugátumok és ezek felhasználása antitest irányított enzimes előgyógyszer terápiában
ATE470714T1 (de) Antikörper gegen doppelintegrinen, zusammensetzungen, verfahren und verwendungen
ATE335515T1 (de) Morpholinobildgebung und therapie
CY1109093T1 (el) Πρωτεϊνες των υποδοχεων θηλαστικων, σχετικα αντιδραστηρια και σχετικες μεθοδοι
EP1908837A3 (de) Menschliche Rezeptorproteine, zugehörige Reagenzien und Verfahren
WO2000074729A3 (en) Alpha or beta emitters to fragments in radioimmunotherapy
ATE235551T1 (de) Ligand (tie ligand-4) vom tie-2 rezeptor und dessen verwendungen
WO1999046379A3 (en) Human receptor proteins; related reagents and methods
YU85501A (sh) Upotreba blokirajućeg monoklonalnog antitela za vla-1 za pripremanje farmaceutskog preparata za tretiranje inflamatornih poremećaja
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
DE60142684D1 (de) Verfahren zur blockierung der zerstörung von gewebe mittels autoreaktiver t-zellen
ES2082132T3 (es) Composicion que contiene al menos dos anticuerpos distintos o fragmentos de ellos.
ES2088464T3 (es) Uso y administracion de enzimas.
Suzuki et al. Solubilization of immune complex deposits by native 7S IgG molecules in lupus glomerulonephritis--a possible antigen excess effect on rheumatoid factor-IgG complexes
WO1999019480A3 (en) Human receptor proteins; related reagents and methods
BR9810574A (pt) Anticorpo monoclonal, fragmento de anticorpo, mistura ou derivado destes, uso dos mesmos, célula, e, preparação farmacêutica.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties